• ES - español
  • EN - English
Parliamentary question - E-002264/2021(ASW)Parliamentary question
E-002264/2021(ASW)

    Answer given by Ms Kyriakides on behalf of the European Commission

    On 17 December 2020, the Commission concluded exploratory talks with Novavax with a view to purchasing its potential vaccine against COVID-19[1]. The envisaged contract with Novavax would provide for the possibility for all EU Member States to purchase 100 million doses, and for further purchase of up to 100 million more doses.

    On 12 January 2021, the Commission concluded explanatory talks with Valneva with a view of purchasing its potential vaccine against COVID-19[2]. The envisaged contract with Valneva would provide for the possibility for all EU Member States to purchase 30 million doses, and for further purchase of up to 30 million more doses.

    Discussions to finalise the contract are ongoing with both of these companies.

    Companies with a promising vaccine candidate, already in or close to starting clinical trials, are invited to contact the Commission. Exploratory talks have taken place with all who have done so. The Commission is not in a position to disclose the names of those with whom it has had such contacts.

    Last updated: 8 July 2021
    Legal notice - Privacy policy